2024
Estimated health effects from domestic use of gaseous fuels for cooking and heating in high-income, middle-income, and low-income countries: a systematic review and meta-analyses. (Journal article)
Puzzolo, E., Fleeman, N., Lorenzetti, F., Rubinstein, F., Li, Y., Xing, R., . . . Pope, D. (2024). Estimated health effects from domestic use of gaseous fuels for cooking and heating in high-income, middle-income, and low-income countries: a systematic review and meta-analyses.. The Lancet. Respiratory medicine, 12(4), 281-293. doi:10.1016/s2213-2600(23)00427-7DOI: 10.1016/s2213-2600(23)00427-7
2023
Chaplin, M., Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Beale, S., . . . Munot, P. (2023). Correction: Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15.. PharmacoEconomics - open, 7(6), 1015. doi:10.1007/s41669-023-00462-7DOI: 10.1007/s41669-023-00462-7
Chaplin, M., Bresnahan, R., Fleeman, N., Mahon, J., Houten, R., Beale, S., . . . Munot, P. (2023). Onasemnogene Abeparvovec for Treating Pre-symptomatic Spinal Muscular Atrophy: An External Assessment Group Perspective of the Partial Review of NICE Highly Specialised Technology Evaluation 15. PharmacoEconomics - Open. doi:10.1007/s41669-023-00439-6DOI: 10.1007/s41669-023-00439-6
Bresnahan, R., Houten, R., Greenhalgh, J., Nevitt, S., Mahon, J., Beale, S., . . . Chaplin, M. (2023). Pegcetacoplan for Treating Paroxysmal Nocturnal Haemoglobinuria: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.. PharmacoEconomics - open. doi:10.1007/s41669-023-00408-zDOI: 10.1007/s41669-023-00408-z
Houten, R., Fleeman, N., Mahon, J., Chaplin, M., Edwards, K., Beale, S., . . . Palmieri, C. (2023). Trastuzumab Deruxtecan for Treating HER2-Positive Unresectable or Metastatic Breast Cancer After Two or More Anti-HER2 Therapies: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN. doi:10.1007/s41669-023-00405-2DOI: 10.1007/s41669-023-00405-2
Huang, Y., Fleeman, N., Doherty, A. J., Wilson, N., Boland, P., Clegg, A., . . . Marson, A. G. (n.d.). Service delivery, behavioural, and self-management interventions for adults with epilepsy. Cochrane Database of Systematic Reviews, 2023(3). doi:10.1002/14651858.cd015284DOI: 10.1002/14651858.cd015284
Fleeman, N., Panebianco, M., Hill, R. A., Doherty, A. J., Nevitt, S. J., Boland, P., . . . Marson, A. G. (n.d.). Service delivery, behavioural, and self-management interventions for children with epilepsy. Cochrane Database of Systematic Reviews, 2023(3). doi:10.1002/14651858.cd015287DOI: 10.1002/14651858.cd015287
2022
Nix, E., Fleeman, N., Lorenzetti, F., Lewis, J., Shen, G., Abebe, L., . . . Puzzolo, E. (2022). Health effects of liquid and gaseous fuels for household energy use: systematic evidence mapping. ENVIRONMENTAL RESEARCH LETTERS, 17(12). doi:10.1088/1748-9326/aca1d2DOI: 10.1088/1748-9326/aca1d2
Fleeman, N., Bradley, P. M., Panebianco, M., & Sharma, A. (2022). Care delivery and self-management strategies for children with epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (4). doi:10.1002/14651858.CD006245.pub5DOI: 10.1002/14651858.CD006245.pub5
2021
Pope, D., Johnson, M., Fleeman, N., Jagoe, K., Duarte, R., Maden, M., . . . Lewis, J. (2021). Are cleaner cooking solutions clean enough? A systematic review and meta-analysis of particulate and carbon monoxide concentrations and exposures. ENVIRONMENTAL RESEARCH LETTERS, 16(8). doi:10.1088/1748-9326/ac13ecDOI: 10.1088/1748-9326/ac13ec
Houten, R., Fleeman, N., Kotas, E., Boland, A., Lambe, T., & Duarte, R. (2021). A systematic review of health state utility values for thyroid cancer. QUALITY OF LIFE RESEARCH, 30(3), 675-702. doi:10.1007/s11136-020-02676-2DOI: 10.1007/s11136-020-02676-2
2020
Stainthorpe, A., Fleeman, N., Houten, R., Chaplin, M., Boland, A., Beale, S., . . . Syndikus, I. (2020). Brentuximab Vedotin for Treating Relapsed or Refractory CD30-Positive Cutaneous T-Cell Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 4(4), 563-574. doi:10.1007/s41669-020-00203-0DOI: 10.1007/s41669-020-00203-0
Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532] (Report)
Greenhalgh, J., Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., . . . Goodson, N. (2020). Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]: Ixekizumab for treating axial spondyloarthritis after NSAIDs[ID1532]. Retrieved from https://www.liverpool.ac.uk/population-health/staff/janette-greenhalgh/
Fleeman, N., Houten, R., Bagust, A., Richardson, M., Beale, S., Boland, A., . . . Shenoy, A. (2020). Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 24(2), 1-+. doi:10.3310/hta24020DOI: 10.3310/hta24020
2019
Fleeman, N., Houten, R., Chaplin, M., Beale, S., Boland, A., Dundar, Y., . . . Shenoy, A. (2019). A systematic review of lenvatinib and sorafenib for treating progressive, locally advanced or metastatic, differentiated thyroid cancer after treatment with radioactive iodine. BMC CANCER, 19(1). doi:10.1186/s12885-019-6369-7DOI: 10.1186/s12885-019-6369-7
Fleeman, N., Mahon, J., Nevitt, S., Duarte, R., Boland, A., Kotas, E., . . . Ahmad, S. (2019). Cenegermin for Treating Neurotrophic Keratitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 3(4), 453-461. doi:10.1007/s41669-019-0138-zDOI: 10.1007/s41669-019-0138-z
Fleeman, N., Bagust, A., Duarte, R., Richardson, M., Nevitt, S., Boland, A., . . . Thorp, N. (2019). Eribulin for Treating Locally Advanced or Metastatic Breast Cancer After One Chemotherapy Regimen: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS-OPEN, 3(3), 293-302. doi:10.1007/s41669-018-0114-zDOI: 10.1007/s41669-018-0114-z
Fleeman, N., Dundar, Y., Shah, P. S., & Shaw, B. N. J. (2019). Heated Humidified High-Flow Nasal Cannula for Preterm Infants: An Updated Systematic Review and Meta-analysis. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 35(4), 298-306. doi:10.1017/S0266462319000424DOI: 10.1017/s0266462319000424
2018
Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (Report)
Fleeman, N., Mahon, J., Chaplin, M., Boland, A., Beale, S., De Sousa Rego Vieira Duarte, R., . . . Green, J. (2018). Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer: Osimertinib for untreated epidermal growth factor receptor (EGFR) mutation-positive non- small-cell lung cancer (17/141/08). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta621/documents/committee-papers
Fleeman, N., Stainthorpe, A., Houten, R., Chaplin, M., Boland, A., Beale, S., . . . Isabel, S. (2018). Brentuximab vedotin for treating relapsed or refractory CD30-positive cutaneous T-cell lymphoma (17/56/12): Brentuximab vedotin for treating relapsed or refractory CD30- positive cutaneous T-cell lymphoma (17/56/12). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta577/documents/committee-papers
Fleeman, N., & Bradley, P. M. (2018). Care delivery and self-management strategies for children with epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (3). doi:10.1002/14651858.C.D006245.pub4DOI: 10.1002/14651858.C.D006245.pub4
Fleeman, N., & Bradley, P. M. (2018). Care delivery and self-management strategies for children with epilepsy.. The Cochrane database of systematic reviews, 3, CD006245. doi:10.1002/14651858.cd006245.pub4DOI: 10.1002/14651858.cd006245.pub4
Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal (Journal article)
Fleeman, N., Abdulla, A., Bagust, A., Beale, S., Richardson, M., Stainthorpe, A., . . . Palmer, D. (2018). Pegylated Liposomal Irinotecan Hydrochloride Trihydrate for Treating Pancreatic Cancer After Gemcitabine: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 36(3), 289-299. doi:10.1007/s40273-017-0592-3DOI: 10.1007/s40273-017-0592-3
2017
Martin, A., Downing, J., Maden, M., Fleeman, N., Alfirevic, A., Haycox, A., & Pirmohamed, M. (2017). An assessment of the impact of pharmacogenomics on health disparities: a systematic literature review. PHARMACOGENOMICS, 18(16), 1541-1550. doi:10.2217/pgs-2017-0076DOI: 10.2217/pgs-2017-0076
Fleeman, N., Bagust, A., Duarte, R., Chaplin, M., Nevitt, S., Boland, A., . . . Thorp, N. (n.d.). Eribulin for treating locally advanced or metastatic breast cancer after one prior chemotherapy regimen (ID1072). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta515/documents/committee-papers
Fleeman, N., Bagust, A., Boland, A., Beale, S., Richardson, M., Krishan, A., . . . Payne, M. (2017). Talimogene Laherparepvec for Treating Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal. PHARMACOECONOMICS, 35(10), 1035-1046. doi:10.1007/s40273-017-0504-6DOI: 10.1007/s40273-017-0504-6
Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer (Report)
Greenhalgh, J. (n.d.). Sorafenib and lenvatinib for treating advanced or metastatic thyroid cancer (ID1059). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta535/documents/committee-papers
2016
Greenhalgh, J. (n.d.). Palbociclib for treating metastatic, hormone receptor-positive, HER2-negative breast cancer (ID915). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta495/documents/committee-papers-2
Greenhalgh, J. (n.d.). Eribulin for locally advanced or metastatic breast cancer (ID964). NICE Website. Retrieved from https://www.nice.org.uk/guidance/gid-ta10030/documents/committee-papers
Greenhalgh, J. (n.d.). Nanoliposomal irinotecan for treating pancreatic cancer after prior treatment with gemcitabine (ID778). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta440/documents/committee-papers-2
Fleeman, N., Mahon, J., Bates, V., Dickson, R., Dundar, Y., Dwan, K., . . . Shaw, B. N. J. (2016). The clinical effectiveness and cost-effectiveness of heated humidified high-flow nasal cannula compared with usual care for preterm infants: systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 20(30), 1-67. doi:10.3310/hta20300DOI: 10.3310/hta20300
Bradley, P. M., Lindsay, B., & Fleeman, N. (2016). Care delivery and self management strategies for adults with epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (2). doi:10.1002/14651858.CD006244.pub3DOI: 10.1002/14651858.CD006244.pub3
Fleeman, N., Bagust, A., Boland, A., Beale, S., Chaplin, M., Krishan, A., . . . Payne, M. (2016). Talimogene laherparepvec for treating metastatic melanoma: Talimogene laherparepvec for treating metastatic melanoma (14/206/04). NICE Website. Retrieved from https://www.nice.org.uk/guidance/gid-tag509/documents/committee-papers-2
2015
Fleeman, N., Bradley, P. M., & Lindsay, B. (2015). Care delivery and self management strategies for children with epilepsy. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (12). doi:10.1002/14651858.CD006245.pub3DOI: 10.1002/14651858.CD006245.pub3
Nicholson, A., Mahon, J., Boland, A., Beale, S., Dwan, K., Fleeman, N., . . . Dundar, Y. (2015). The clinical effectiveness and cost-effectiveness of the PROGENSA (R) prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation. Health Technology Assessment, 19(87), 1-+. doi:10.3310/hta19870DOI: 10.3310/hta19870
Fleeman, N., Bagust, A., Beale, S., Boland, A., Dickson, R., Dwan, K., . . . Banks, L. (2015). Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective. PHARMACOECONOMICS, 33(9), 893-904. doi:10.1007/s40273-015-0276-9DOI: 10.1007/s40273-015-0276-9
Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab (Report)
Fleeman, N., Bagust, A., Chaplin, M., Krishan, A., Boland, A., Beale, S., . . . Payne, M. (2015). Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab: Pembrolizumab for treating unresectable, metastatic melanoma after progression with ipilimumab (14/177/07). NICE Website. Retrieved from https://www.nice.org.uk/
Ciclosporin for treating dry eye disease (Report)
Fleeman, N., Bagust, A., Beale, S., Boland, A., Dwan, K., Kotas, E., . . . Ahmad, S. (2015). Ciclosporin for treating dry eye disease: Ciclosporin for treating dry eye disease (13/166/01). NICE Website. Retrieved from https://www.nice.org.uk/
Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Oyee, J., Trevor, N., Beale, S., . . . O'Reilly, S. (2015). Eribulin for the Treatment of Advanced or Metastatic Breast Cancer: A NICE Single Technology Appraisal. PharmacoEconomics, 33(2), 137-148. doi:10.1007/s40273-014-0214-2DOI: 10.1007/s40273-014-0214-2
Shabaruddin, F. H., Fleeman, N. D., & Payne, K. (2015). Economic evaluations of personalized medicine: existing challenges and current developments. PHARMACOGENOMICS & PERSONALIZED MEDICINE, 8, 115-126. doi:10.2147/PGPM.S35063DOI: 10.2147/PGPM.S35063
Protogerou, C., Fleernan, N., Dwan, K., Richardson, M., Dundar, Y., & Hagger, M. S. (2015). Moderators of the effect of psychological interventions on depression and anxiety in cardiac surgery patients: A systematic review and meta-analysis. BEHAVIOUR RESEARCH AND THERAPY, 73, 151-164. doi:10.1016/j.brat.2015.08.004DOI: 10.1016/j.brat.2015.08.004
Fleeman, N., Bagust, A., Beale, S., Dwan, K., Dickson, R., Proudlove, C., & Dundar, Y. (2015). Pertuzumab in Combination with Trastuzumab and Docetaxel for the Treatment of HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer. PHARMACOECONOMICS, 33(1), 13-23. doi:10.1007/s40273-014-0206-2DOI: 10.1007/s40273-014-0206-2
Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Dwan, K., Beale, S., Fleeman, N., . . . Fisher, M. (2015). Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 19(29), 1-+. doi:10.3310/hta19290DOI: 10.3310/hta19290
2014
Deferasirox for managing iron overload in people with myelodysplastic syndrome (Journal article)
Meerpohl, J. J., Schell, L. K., Ruecker, G., Fleeman, N., Motschall, E., Niemeyer, C. M., & Bassler, D. (2014). Deferasirox for managing iron overload in people with myelodysplastic syndrome. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (10). doi:10.1002/14651858.CD007461.pub3DOI: 10.1002/14651858.CD007461.pub3
Fleeman, N., Bagust, A., Boland, A., Dwan, K., Chaplin, M., Beale, S., . . . Greystoke, A. (2014). Nintedanib for previously treated locally advanced or metastatic non small cell lung cancer: Nintedanib for previously treated locally advanced or metastatic non-small cell lung cancer (13/106/01). NICE Website. Retrieved from https://www.nice.org.uk/
Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma (Report)
Fleeman, N., Bagust, A., Beale, S., Boland, A., Dickson, R., Dwan, K., . . . Banks, L. (2014). Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma: Dabrafenib for treating unresectable, advanced or metastatic BRAFv600 mutation- positive melanoma (12/54). NICE Website. Retrieved from https://www.nice.org.uk/guidance/ta321/history
Deferasirox for managing transfusional iron overload in people with sickle cell disease (Journal article)
Meerpohl, J. J., Schell, L. K., Ruecker, G., Motschall, E., Fleeman, N., Niemeyer, C. M., & Bassler, D. (2014). Deferasirox for managing transfusional iron overload in people with sickle cell disease. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (5), 1-77. doi:10.1002/14651858.CD007477.pub3DOI: 10.1002/14651858.CD007477.pub3
Allopurinol for the treatment of chronic kidney disease: a systematic review (Journal article)
Fleeman, N., Pilkington, G., Dundar, Y., Dwan, K., Boland, A., Dickson, R., . . . Pyatt, J. (2014). Allopurinol for the treatment of chronic kidney disease: a systematic review. HEALTH TECHNOLOGY ASSESSMENT, 18(40), 1-+. doi:10.3310/hta18400DOI: 10.3310/hta18400
EFFICACY OF PSYCHOLOGICAL INTERVENTIONS TO REDUCE DISTRESS IN PATIENTS UNDERGOING INVASIVE CARDIAC PROCEDURES: A META-ANALYSIS (Conference Paper)
Protogerou, C., Fleeman, N. F., Dwain, K. D., Richardson, M. R., Dundar, Y. D., & Dickson, R. D. (2014). EFFICACY OF PSYCHOLOGICAL INTERVENTIONS TO REDUCE DISTRESS IN PATIENTS UNDERGOING INVASIVE CARDIAC PROCEDURES: A META-ANALYSIS. In INTERNATIONAL JOURNAL OF BEHAVIORAL MEDICINE Vol. 21 (pp. S63). Retrieved from https://www.webofscience.com/
2013
Are health technology assessments of pharmacogenetic tests feasible? A case study of <i>CYP2D6</i> testing in the treatment of breast cancer with tamoxifen (Journal article)
Fleeman, N., Payne, K., Newman, W. G., Howell, S. J., Boland, A., Oyee, J., . . . Dickson, R. (2013). Are health technology assessments of pharmacogenetic tests feasible? A case study of <i>CYP2D6</i> testing in the treatment of breast cancer with tamoxifen. PERSONALIZED MEDICINE, 10(6), 601-611. doi:10.2217/pme.13.60DOI: 10.2217/pme.13.60
2012
Deferasirox for managing iron overload in people with thalassaemia (Journal article)
Meerpohl, J. J., Antes, G., Ruecker, G., Fleeman, N., Motschall, E., Niemeyer, C. M., & Bassler, D. (2012). Deferasirox for managing iron overload in people with thalassaemia. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (2). doi:10.1002/14651858.CD007476.pub2DOI: 10.1002/14651858.CD007476.pub2
2011
The clinical effectiveness and cost-effectiveness of genotyping for <i>CYP2D6</i> for the management of women with breast cancer treated with tamoxifen: a systematic review (Journal article)
Fleeman, N., Martin Saborido, C., Payne, K., Boland, A., Dickson, R., Dundar, Y., . . . Walley, T. (2011). The clinical effectiveness and cost-effectiveness of genotyping for <i>CYP2D6</i> for the management of women with breast cancer treated with tamoxifen: a systematic review. HEALTH TECHNOLOGY ASSESSMENT, 15(33), XIII-+. doi:10.3310/hta15330DOI: 10.3310/hta15330
Cetuximab nel carcinoma ricorrente e/o metastatico a cellule squamose della testa e del collo. Una valutazione di tecnologia singola del NICE (Journal article)
Bagust, A., Greenhalgh, J., Boland, A., Fleeman, N., McLeod, C., Dickson, R., . . . Shaw, R. (2011). Cetuximab nel carcinoma ricorrente e/o metastatico a cellule squamose della testa e del collo. Una valutazione di tecnologia singola del NICE. PharmacoEconomics Italian Research Articles, 13(2), 101-110. doi:10.1007/bf03320687DOI: 10.1007/bf03320687
Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses (Journal article)
Fleeman, N., Dundar, Y., Dickson, R., Jorgensen, A., Pushpakom, S., McLeod, C., . . . Walley, T. (2011). Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. PHARMACOGENOMICS JOURNAL, 11(1), 1-14. doi:10.1038/tpj.2010.73DOI: 10.1038/tpj.2010.73
Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis (Journal article)
Fleeman, N., Bagust, A., Boland, A., Dickson, R., Dundar, Y., Moonan, M., . . . Thorp, N. (2011). Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. HEALTH TECHNOLOGY ASSESSMENT, 15(42), 1-+. doi:10.3310/hta15420DOI: 10.3310/hta15420
2010
Deferasirox for managing iron overload in people with myelodysplastic syndrome (Journal article)
Meerpohl, J. J., Antes, G., Ruecker, G., Fleeman, N., Motschall, E., Niemeyer, C. M., & Bassler, D. (2010). Deferasirox for managing iron overload in people with myelodysplastic syndrome. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (11). doi:10.1002/14651858.CD007461.pub2DOI: 10.1002/14651858.CD007461.pub2
Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (Journal article)
Greenhalgh, J., McLeod, C., Bagust, A., Boland, A., Fleeman, N., Dundar, Y., . . . Pearson, M. (n.d.). Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment, 14(Suppl 2), 33-39. doi:10.3310/hta14suppl2-05DOI: 10.3310/hta14suppl2-05
Deferasirox for managing transfusional iron overload in people with sickle cell disease (Journal article)
Meerpohl, J. J., Antes, G., Ruecker, G., Fleeman, N., Niemeyer, C., & Bassler, D. (2010). Deferasirox for managing transfusional iron overload in people with sickle cell disease. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, (8). doi:10.1002/14651858.CD007477.pub2DOI: 10.1002/14651858.CD007477.pub2
Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck A NICE Single Technology Appraisal (Journal article)
Bagust, A., Greenhalgh, J., Boland, A., Fleeman, N., McLeod, C., Dickson, R., . . . Shaw, R. (2010). Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck A NICE Single Technology Appraisal. PHARMACOECONOMICS, 28(6), 439-448. doi:10.2165/11532220-000000000-00000DOI: 10.2165/11532220-000000000-00000
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (Journal article)
Fleeman, N., Bagust, A., McLeod, C., Greenhalgh, J., Boland, A., Dundar, Y., . . . Pearson, M. (n.d.). Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. Health Technology Assessment, 14(Suppl 1), 47-53. doi:10.3310/hta14suppl1-07DOI: 10.3310/hta14suppl1-07
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Fleeman, N., McLeod, C., . . . Fisher, M. (n.d.). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. Health Technology Assessment, 14(Suppl 1), 31-38. doi:10.3310/hta14suppl1-05DOI: 10.3310/hta14suppl1-05
Abatacept for the treatment of rheumatoid arthritis (Journal article)
Hockenhull, J., Boland, A., Bagust, A., Dundar, Y., Fleeman, N., Kennedy, T., . . . Dickson, R. (2010). Abatacept for the treatment of rheumatoid arthritis. Health Technology Assessment. Retrieved from http://www.hta.ac.uk/project/1648.asp
Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (Journal article)
Fleeman, N., Bagust, A., McLeod, C., Greenhalgh, J., Boland, A., Dundar, Y., . . . Pearson, M. (2010). Pemetrexed for the first-line treatment of locally advanced or metastatic non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 14, 47-53. doi:10.3310/hta14suppl1/07DOI: 10.3310/hta14suppl1/07
Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer (Journal article)
Greenhalgh, J., McLeod, C., Bagust, A., Boland, A., Fleeman, N., Dundar, Y., . . . Pearson, M. (2010). Pemetrexed for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer. HEALTH TECHNOLOGY ASSESSMENT, 14, 33-39. doi:10.3310/hta14suppl2/05DOI: 10.3310/hta14suppl2/05
Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Saborido, C. M., Fleeman, N., McLeod, C., . . . Fisher, M. (2010). Prasugrel for the treatment of acute coronary artery syndromes with percutaneous coronary intervention. HEALTH TECHNOLOGY ASSESSMENT, 14, 31-38. doi:10.3310/hta14suppl1/05DOI: 10.3310/hta14suppl1/05
The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation (Journal article)
Fleeman, N., McLeod, C., Bagust, A., Beale, S., Boland, A., Dundar, Y., . . . Dickson, R. (2010). The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 14(3), 1-+. doi:10.3310/hta14030DOI: 10.3310/hta14030
2009
Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Fleeman, N., McLeod, C., Dundar, Y., . . . Shaw, R. (n.d.). Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. Health Technology Assessment, 13(Suppl 3), 49-54. doi:10.3310/hta13suppl3-08DOI: 10.3310/hta13suppl3-08
Rituximab for the treatment of rheumatoid arthritis (Journal article)
Bagust, A., Boland, A., Hockenhull, J., Fleeman, N., Greenhalgh, J., Dundar, Y., . . . Dickson, R. (n.d.). Rituximab for the treatment of rheumatoid arthritis. Health Technology Assessment, 13(Suppl 2), 23-29. doi:10.3310/hta13suppl2-04DOI: 10.3310/hta13suppl2-04
Providing patients with information on pharmacogenetic testing (Journal article)
Fleeman, N., & Dickson, R. (2009). Providing patients with information on pharmacogenetic testing. Nursing Standard, 23(21), 46-51. doi:10.7748/ns.23.21.46.s51DOI: 10.7748/ns.23.21.46.s51
Providing patients with information on pharmacogenetic testing. (Journal article)
Fleeman, N., & Dickson, R. (2009). Providing patients with information on pharmacogenetic testing.. Nursing standard (Royal College of Nursing (Great Britain) : 1987), 23(21), 46-48. doi:10.7748/ns2009.01.23.21.46.c6768DOI: 10.7748/ns2009.01.23.21.46.c6768
Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck (Journal article)
Greenhalgh, J., Bagust, A., Boland, A., Fleeman, N., McLeod, C., Dundar, Y., . . . Shaw, R. (2009). Cetuximab for the treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck. HEALTH TECHNOLOGY ASSESSMENT, 13, 49-54. doi:10.3310/hta13suppl3/08DOI: 10.3310/hta13suppl3/08
Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation (Journal article)
McLeod, C., Fleeman, N., Kirkham, J., Bagust, A., Boland, A., Chu, P., . . . Walley, T. (2009). Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anaemia: a systematic review and economic evaluation. HEALTH TECHNOLOGY ASSESSMENT, 13(1), 1-+. doi:10.3310/hta13010DOI: 10.3310/hta13010
Rituximab for the treatment of rheumatoid arthritis (Journal article)
Bagust, A., Boland, A., Hockenhull, J., Fleeman, N., Greenhalgh, J., Dundar, Y., . . . Dickson, R. (2009). Rituximab for the treatment of rheumatoid arthritis. HEALTH TECHNOLOGY ASSESSMENT, 13, 23-29. doi:10.3310/hta13suppl2/04DOI: 10.3310/hta13suppl2/04
2008
Deferasirox for managing iron overload in patients with myelodysplastic syndrome (Journal article)
Meerpohl, J. J., Antes, G., Rücker, G., McLeod, C., Fleeman, N., Niemeyer, C., & Bassler, D. (n.d.). Deferasirox for managing iron overload in patients with myelodysplastic syndrome. doi:10.1002/14651858.cd007461DOI: 10.1002/14651858.cd007461
Deferasirox for managing iron overload in people with thalassaemia (Journal article)
Meerpohl, J. J., Antes, G., Rücker, G., McLeod, C., Fleeman, N., Niemeyer, C. M., & Bassler, D. (n.d.). Deferasirox for managing iron overload in people with thalassaemia. doi:10.1002/14651858.cd007476DOI: 10.1002/14651858.cd007476
Deferasirox for managing transfusional iron overload in people with sickle cell disease (Journal article)
Meerpohl, J. J., Antes, G., Rücker, G., McLeod, C., Fleeman, N., Niemeyer, C., & Bassler, D. (n.d.). Deferasirox for managing transfusional iron overload in people with sickle cell disease. doi:10.1002/14651858.cd007477DOI: 10.1002/14651858.cd007477
So many filters, so little time: the development of a search filter appraisal checklist (Journal article)
Glanville, J., Bayliss, S., Booth, A., Dundar, Y., Fernandes, H., Fleeman, N. D., . . . Welch, K. (2008). So many filters, so little time: the development of a search filter appraisal checklist. JOURNAL OF THE MEDICAL LIBRARY ASSOCIATION, 96(4), 356-361. doi:10.3163/1536-5050.96.4.011DOI: 10.3163/1536-5050.96.4.011
2000
A prospective health impact assessment of the Merseyside Integrated Transport Strategy (MerITS) (Journal article)
Fleeman, N., & Scott-Samuel, A. (2000). A prospective health impact assessment of the Merseyside Integrated Transport Strategy (MerITS). JOURNAL OF PUBLIC HEALTH MEDICINE, 22(3), 268-274. Retrieved from https://www.webofscience.com/
1997
Alcohol home detoxification: a literature review. (Journal article)
Fleeman, N. D. (1997). Alcohol home detoxification: a literature review.. Alcohol and alcoholism (Oxford, Oxfordshire), 32(6), 649-656. doi:10.1093/oxfordjournals.alcalc.a008315DOI: 10.1093/oxfordjournals.alcalc.a008315
Undated
Puzzolo, E., Fleeman, N., Lorenzetti, F., Rubinstein, F., Li, Y., Xing, R., . . . Pope, D. (n.d.). Health Effects from Domestic Use of Gaseous and Liquid Fuels for Cooking and Heating in High, Middle and Low-Income Countries: A Systematic Review and Meta-Analysis.
